
\begin{tabular}{l|l|l|r}
\hline
Restricted Model & Unrestricted Model & Sample & P-Value\\
\hline
Pr(Complier| Block + Resample Indicators) & Pr(Complier| Block + Resample +  VAW Treatment Indicators) & All Respondents (ML, N = 5528) & 0.517\\
\hline
Pr(Complier| Block + Resample Indicators) & Pr(Complier| Block + Resample + 7 Treatment Condition Indicators) & All Respondents (ML, N = 5528) & 0.107\\
\hline
Pr(Complier| Block + Resample Indicators) & Pr(Complier| Block + Resample +  VAW Treatment Indicators) & Women (ML, N = 2743) & 0.254\\
\hline
Pr(Complier| Block + Resample Indicators) & Pr(Complier| Block + Resample + 7 Treatment Condition Indicators) & Women (ML, N = 2743) & 0.164\\
\hline
Pr(Complier| Block + Resample Indicators) & Pr(Complier| Block + Resample +  VAW Treatment Indicators) & Men (ML, N = 2785) & 0.916\\
\hline
Pr(Complier| Block + Resample Indicators) & Pr(Complier| Block + Resample + 7 Treatment Condition Indicators) & Men (ML, N = 2785) & 0.217\\
\hline
E(N Compliers| Block + Resample Indicators) & E(N Compliers| Block + Resample +  VAW Treatment Indicators) & 110 Clusters & 0.527\\
\hline
E(N Compliers| Block + Resample Indicators) & E(N Compliers| Block + Resample + 7 Treatment Condition Indicators) & 110 Clusters & 0.122\\
\hline
E(N Women Compliers| Block + Resample Indicators) & E(N Compliers| Block + Resample +  VAW Treatment Indicators) & 110 Clusters & 0.253\\
\hline
E(N Women Compliers| Block + Resample Indicators) & E(N Compliers| Block + Resample + 7 Treatment Condition Indicators) & 110 Clusters & 0.231\\
\hline
E(N Men Compliers| Block + Resample Indicators) & E(N Compliers| Block + Resample +  VAW Treatment Indicators) & 110 Clusters & 0.967\\
\hline
E(N Men Compliers| Block + Resample Indicators) & E(N Compliers| Block + Resample + 7 Treatment Condition Indicators) & 110 Clusters & 0.127\\
\hline
\end{tabular}
